Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine vs dexamethasone-containing antiemetic regimens for delayed CINV after autologous HSCT
ChiCTR2500110061Phase 3Not yet recruiting
- Sponsor
- The Affiliated People’s Hospital of Ningbo University
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of olanzapine, dexamethasone, fosaprepitant and tropisetron in multiple myeloma (MM) and chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by The Affiliated People’s Hospital of Ningbo University. Primary endpoint: Complete response (CR) rate for delayed CINV. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
olanzapinedexamethasonefosaprepitanttropisetron
03
Conditions
multiple myeloma (MM)chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2500110061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110061.